Abstracts tagged "risk factors"

Abstract Number: 1888 • ACR Convergence 2024
Anti-Spike Antibodies Protect Against COVID-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the SUCCEED Study
Jeremiah Tan¹, J. Antonio Avina-Zubieta², Paul Fortin³, Anne-Claude Gingras⁴, Maggie Larche⁵, Dawn Bowdish⁵, Claudie Berger⁶, Ines Colmegna⁷, Carol Hitchon⁸, Diane Lacaille², Dawn Richards⁹, Nadine Lalonde¹⁰, Ayesha Kirmani¹, Jennifer Lee¹¹ and Sasha Bernatsky⁶, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁴Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Canadian Arthritis Patients Alliance, Toronto, ON, Canada, ¹⁰COVID-19 Global Rheumatology Alliance, London, ON, Canada, ¹¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: People with immune-mediated inflammatory diseases (IMIDs) may be more vulnerable to severe COVID-19 outcomes. COVID-19 vaccination is a key element in mitigating this risk.…
Abstract Number: 2499 • ACR Convergence 2024
Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease shock syndrome (KDSS) is a phenotype of Kawasaki disease (KD) associated with higher rates of refractory KD (RKD) and coronary artery aneurysms…
Abstract Number: 0135 • ACR Convergence 2024
Rheumatoid Arthritis Associated Risk of Venous Thromboembolism Is Not Dependent on Disease Duration: United Kingdom Based Population Study
James Galloway¹, Victoria Basey², Saqib Rana³, Simon de Lusignan⁴ and Maya H. Buch⁵, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Pfizer UK, Tadworth, United Kingdom, ³Pfizer, Tadworth, United Kingdom, ⁴Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, ⁵Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Risk of venous thromboembolism (VTE) is higher in patients with rheumatoid arthritis (RA) compared to the general population; however whether this risk changes with…
Abstract Number: 0722 • ACR Convergence 2024
Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis
Andrea Hinojosa-Azaola¹, Marlon Sandino-Bermúdez², Ana Sarahí Mulia-Soto³, Juan M. Mejía-Vilet⁴ and Eduardo Martin Nares⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, ⁴Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) encompass a group of systemic inflammatory diseases with multi-organ involvement. Relapses occur in 14-44% of patients within 18-36 months…
Abstract Number: 1094 • ACR Convergence 2024
Longitudinal Analysis of Serum Urate in Prediabetic Phase
Javier Marrugo¹, Leah Santacroce¹, Misti Paudel², Sho Fukui³, Sara Tedeschi¹ and Daniel Solomon⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: More than 460 million people worldwide are currently living with prediabetes, a condition that not only predisposes individuals to diabetes (DM) but also to…
Abstract Number: 1895 • ACR Convergence 2024
Association Between a History of Mental Illness and the Risk of Systemic Autoimmune Rheumatic Diseases: A Nationwide, Population-based Case-control Study
Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: Clinical studies have shown high prevalence rates of mental illnesses in patients with autoimmune diseases. A recent animal study revealed that social stress induces…
Abstract Number: 2500 • ACR Convergence 2024
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…
Abstract Number: 0172 • ACR Convergence 2024
Effectiveness of mRNA COVID-19 Vaccines in Patients with Rheumatologic Conditions on Immunosuppressive Therapies
Brandon Levian¹, Charlotte Botz², Jason Chwa², Sophie Grove², Vignesh Ravi², Branden Ireifej³, daniel arkfeld⁴, Diana Hanna², Jenny Hu² and Binh Ngo², ¹Keck School of Medicine, Beverly Hills, CA, ²Keck School of Medicine, Los Angeles, ³LAGMC/Keck School of Medicine, Los Angeles, CA, ⁴Keck Medical Center of USC, RANCHO PALOS VERDES, CA
Background/Purpose: Despite extensive data supporting the effectiveness of mRNA vaccines against SARS-CoV-2 in immunocompetent individuals, their efficacy in immunosuppressed patients remains uncertain. Consequently, this study…
Abstract Number: 0744 • ACR Convergence 2024
Cerebrovascular Accidents (CVA) in Giant Cell Arteritis: Identification of Predictive Factors from the ARTESER Registry
Adrián Martín-Gutiérrez¹, Juan Molina-Collada², Marta Domínguez-Álvaro³, Rafael Benito Melero-Gonzalez⁴, Elisa Fernández-Fernández:⁵, Maite Silva-Diaz⁶, Jesús Alejandro Valero⁷, Ismael Gonzalez⁸, Julio Sánchez-Martín⁹, Javier Narvaez-García¹⁰, Itziar Calvo¹¹, Vicente Aldasoro¹², lydia Abasolo Alcazar¹³, ALBERTO MARIANO RUIZ ROMAN¹⁴, Javier Loricera¹⁵, Santos Castañeda¹⁶, Clara Molina Almela¹⁷, María Alcalde Villar:¹⁸, Antonio Juan-Mas¹⁹ and Ricardo Blanco-Alonso²⁰, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴CHU Ourense, O Carballino, Spain, ⁵La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁶Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁷Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, ⁸Complejo Asistencial Universitario de Leon, León, Spain, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ¹¹Hospital Universitario de Basurto, Bilbao, Spain, ¹²Hospital Universitario de Navarra, Pamplona, Spain, ¹³IdISSC. HCSC, Madrid, Spain, ¹⁴Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁶Hospital Universitario de la Princesa, Madrid, Spain, ¹⁷Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ¹⁸Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, ¹⁹Rheumatology Department, Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Cantabria, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis in the elderly and involves the large and medium-sized vessels. Cerebrovascular accidents…
Abstract Number: 1106 • ACR Convergence 2024
Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Clara Moriano⁴, Javier Narvaez-García⁵, Vicente Aldasoro⁶, Olga Maíz Alonso⁷, Iñigo Hernández-Rodríguez⁸, Paloma Vela-Casasempere⁹, Susana Romero Yuste¹⁰, Eugenio De Miguel¹¹, Eva Galindez-Agirregoikoa¹², Jesus C. Fernandez-López¹³, ivan Ferraz-Amaro¹⁴, Julio Sánchez-Martín¹⁵, José Luis Callejas¹⁶, Patricia Moya Albarado¹⁷, Cristina Campos Fernández¹⁸, Fernando Lopez-Gutierrez¹⁹, Santos Castañeda²⁰ and Ricardo Blanco-Alonso²¹, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital León, LEON, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷3Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, ⁸Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital General Universitario Alicante, Alicante, Spain, ¹⁰Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ¹¹Hospital Universitario La Paz, Madrid, Spain, ¹²BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹³11Rheumatology, Hospital Universitario Juan Canalejo, A Coruña, Spain., A Coruña, Spain, ¹⁴Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ¹⁷Hospital de San Pau, Barcelona, Spain, ¹⁸Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²⁰Hospital Universitario de la Princesa, Madrid, Spain, ²¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biological drug approved for the treatment of giant cell arteritis (GCA). Clinical trials were performed with intravenous (IV) and…
Abstract Number: 1901 • ACR Convergence 2024
Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study
James Galloway¹, Victoria Basey², Michael Mclean², Simon de Lusignan³ and Maya H. Buch⁴, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Pfizer UK, Tadworth, United Kingdom, ³Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, ⁴Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Risk of venous thromboembolism (VTE) is increased in people with rheumatoid arthritis (RA) when compared to the general population, but the variation of this…
Abstract Number: 2566 • ACR Convergence 2024
Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
andriko Palmowski¹, Zhivana Boydzhieva², Paula Hoff³, Sandra Hermann³, burkhard Muche³, David Simon⁴, Gerhard Krönke³, Edgar Wiebe⁵ and FRANK HARTMUT DR. BUTTGEREIT⁵, ¹Charité - Universittsmedizin Berlin, Berlin, Germany, ²Charité Universittsmedizin, Berlin, Germany, ³Rheumatology, Charité, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: In a previous study, we found daily proton pump inhibitor (PPI) intake to be associated with decreased bone mineral density in patients with inflammatory…
Abstract Number: 0192 • ACR Convergence 2024
Associations Between Social Determinants of Health and Acute Care Use Among Individuals with Lupus, Rheumatoid Arthritis and Osteoarthritis in the All of Us Research Program
Candace Feldman¹, Leah Santacroce¹, Yomaira Silva², Jing Cui¹, Jeong Yee¹, Elizabeth Karlson¹ and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Adverse social determinants of health (SDoH), or social risk factors like economic insecurities, inadequate health care access and neighborhood vulnerability, contribute to modifiable inequities…
Abstract Number: 0761 • ACR Convergence 2024
An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis
Ioannis Koulas¹, Nikolaos Tsaftaridis², Ivana Ilic³, Jack Jnani⁴, Alex Spyropoulos¹ and Lara El Khoury⁵, ¹Feinstein Institutes for Medical Research/Northwell Health, Manhasset, ²Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, ³Northwell, Brooklyn, NY, ⁴Department of Medicine/Northwell Health, Manhasset, ⁵Division of Rheumatology/Northwell Health, Great Neck, NY
Background/Purpose: Studies indicating a higher incidence rate of stroke and venous thromboembolism (VTE) among patients with giant cell arteritis (GCA) hint at a possible association between…
Abstract Number: 1124 • ACR Convergence 2024
Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids
Xiaodi Ruan¹, Michael Williams², Gul Karakoc¹, Elizabeth McNeer¹, Leena Choi¹, Jonathan D. Mosley¹, C. Michael Stein¹ and Vivian K. Kawai¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²VUMC, Nashville, TN
Background/Purpose: Glucocorticoids (GCs) are potent anti-inflammatory drugs that are commonly prescribed, particularly for rheumatic and immunologic conditions. Hyperglycemia is an important adverse effect and occurs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].